These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 1625193

  • 1. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
    Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ.
    J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
    [Abstract] [Full Text] [Related]

  • 2. In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.
    Kivlighn SD, Zingaro GJ, Gabel RA, Broten TP, Schorn TW, Schaffer LW, Naylor EM, Chakravarty PK, Patchett AA, Greenlee WJ.
    Am J Hypertens; 1995 Jan; 8(1):58-66. PubMed ID: 7734099
    [Abstract] [Full Text] [Related]

  • 3. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
    Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
    [Abstract] [Full Text] [Related]

  • 4. In vivo pharmacology of L-159,913, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
    Gabel RA, Kivlighn SD, Zingaro GJ, Schorn TW, Schaffer LW, Ashton WT, Chang LL, Flanagan K, Greenlee WJ, Siegl PK.
    Clin Exp Hypertens; 1995 Aug; 17(6):931-53. PubMed ID: 7581262
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K.
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [Abstract] [Full Text] [Related]

  • 6. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
    Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB.
    J Pharmacol Exp Ther; 1990 Feb; 252(2):719-25. PubMed ID: 2179531
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J.
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [Abstract] [Full Text] [Related]

  • 8. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
    Cazes M, Provost D, Versigny A, Cloarec A.
    Eur J Pharmacol; 1995 Sep 15; 284(1-2):157-70. PubMed ID: 8549620
    [Abstract] [Full Text] [Related]

  • 9. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
    Morita O, Kushida H, Kunihara M.
    J Cardiovasc Pharmacol; 1995 Jun 15; 25(6):880-7. PubMed ID: 7564332
    [Abstract] [Full Text] [Related]

  • 10. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.
    Chang RS, Siegl PK, Clineschmidt BV, Mantlo NB, Chakravarty PK, Greenlee WJ, Patchett AA, Lotti VJ.
    J Pharmacol Exp Ther; 1992 Jul 15; 262(1):133-8. PubMed ID: 1625192
    [Abstract] [Full Text] [Related]

  • 11. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
    Bunting MW, Widdop RE.
    Br J Pharmacol; 1995 Dec 15; 116(8):3181-90. PubMed ID: 8719794
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II receptor subtypes in renal cortex of rats and rhesus monkeys.
    Gibson RE, Thorpe HH, Cartwright ME, Frank JD, Schorn TW, Bunting PB, Siegl PK.
    Am J Physiol; 1991 Sep 15; 261(3 Pt 2):F512-8. PubMed ID: 1653532
    [Abstract] [Full Text] [Related]

  • 13. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
    Wong PC, Hart SD, Chiu AT, Herblin WF, Carini DJ, Smith RD, Wexler RR, Timmermans PB.
    J Pharmacol Exp Ther; 1991 Nov 15; 259(2):861-70. PubMed ID: 1941632
    [Abstract] [Full Text] [Related]

  • 14. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
    Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB.
    J Pharmacol Exp Ther; 1990 Feb 15; 252(2):726-32. PubMed ID: 2179532
    [Abstract] [Full Text] [Related]

  • 15. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
    Ohlstein EH, Gellai M, Brooks DP, Vickery L, Jugus J, Sulpizio A, Ruffolo RR, Weinstock J, Edwards RM.
    J Pharmacol Exp Ther; 1992 Aug 15; 262(2):595-601. PubMed ID: 1501114
    [Abstract] [Full Text] [Related]

  • 16. In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.
    Kivlighn SD, Zingaro GJ, Gabel RA, Broten TP, Chang RS, Ondeyka DL, Mantlo NB, Gibson RE, Greenlee WJ, Siegl PK.
    Eur J Pharmacol; 1995 Dec 29; 294(2-3):439-50. PubMed ID: 8750704
    [Abstract] [Full Text] [Related]

  • 17. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
    Wienen W, Mauz AB, Van Meel JC, Entzeroth M.
    Mol Pharmacol; 1992 Jun 29; 41(6):1081-8. PubMed ID: 1614410
    [Abstract] [Full Text] [Related]

  • 18. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs.
    Wong PC, Hart SD, Duncia JV, Timmermans PB.
    Eur J Pharmacol; 1991 Sep 24; 202(3):323-30. PubMed ID: 1748155
    [Abstract] [Full Text] [Related]

  • 19. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y, Wada T, Shibouta Y, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T.
    J Pharmacol Exp Ther; 1994 Mar 24; 268(3):1540-7. PubMed ID: 8138966
    [Abstract] [Full Text] [Related]

  • 20. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
    Cirillo R, Renzetti AR, Cucchi P, Guelfi M, Salimbeni A, Caliari S, Castellucci A, Evangelista S, Subissi A, Giachetti A.
    Br J Pharmacol; 1995 Mar 24; 114(6):1117-24. PubMed ID: 7620700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.